WO2000034230A1 - 4-3-substituted-amino-cyclobut-3-ene-1,2-diones and use for influencing smooth muscle contraction - Google Patents
4-3-substituted-amino-cyclobut-3-ene-1,2-diones and use for influencing smooth muscle contraction Download PDFInfo
- Publication number
- WO2000034230A1 WO2000034230A1 PCT/US1999/028618 US9928618W WO0034230A1 WO 2000034230 A1 WO2000034230 A1 WO 2000034230A1 US 9928618 W US9928618 W US 9928618W WO 0034230 A1 WO0034230 A1 WO 0034230A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbon atoms
- pharmaceutically acceptable
- acceptable salt
- phenyl
- cyclobut
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
Definitions
- TITLE 4-3-SUBSTITUTED-AMINO-CYCL0BUT-3-ENE-l,2-DI0NES AND USE FOR INFLUENCIN SMOOTH MUSCLE CONTRACTION
- the present invention relates to a novel series of 4- substituted-3-substituted-amino-cyclobut-3-ene-l , 2-diones having pharmacological activity, to a process for their preparation, to pharmaceutical compositions containing them, and to their use in the treatment of disorders associated with smooth muscle contraction, via potassium channel modulation.
- disorders include, but are not limited to: urinary incontinence, asthma, premature labor, irritable bowel syndrome, congestive heart failure, angina, and cerebral vascular disease.
- K ATP ATP-dependent potassium channel
- N-aryl and N-heteroaryl-1, 2- diaminocyclobutene-3 , 4-diones as useful agents for the treatment of cardiovascular disorders, metabolic disorders, central nervous system disorders, bronchial asthma, and irritable bladder.
- the 4-substituted-3-disubstituted-amino-cyclobut-3- ene-1, 2-diones described herein are useful in the treatment of disorders associated with smooth muscle contraction, via potassium channel modulation.
- R 1 , R 2 , and R 3 are, independently hydrogen, halogen, nitro, cyano, alkyl of 1 to 10 carbon atoms (optionally substituted with halogen) , cycloalkyl of 3 to 10 carbon atoms, -OR 7 , amino, alkylamino of 1 to 10 carbon atoms, - S0 3 H, -S0 2 NH 2 , -SONH 2 , -NHS0 2 R 7 , ft
- W is selected from the group consisting of carbon and nitrogen and wherein the carbon atom may be optionally substituted with -R j -R 2 and -R 3 .
- R 4 is a alkyl of 1 to 10 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, aralkyl of 7 to 20 carbon atoms, wherein the aryl group is optionally substituted with alkyl of 1 to 10 carbon atoms, nitro, halogen, cyano, -OR,,
- R 5 is hydrogen, alkyl of 1 to 10 carbon atoms, formyl, alkanoyl of 2 to 7 carbon atoms, alkenoyl of 3 to 7 carbon atoms ,
- aroyl of 7 to 12 carbon atoms arylalkenoyl of 9 to 20 carbon atoms, arylsulfonyl of 6 to 12 carbon atoms, arylalkanoyl of 8 to 12 carbon atoms or arylalkylsulfonyl of 7 to 12 carbon atoms;
- R 6 is alkyl of 1 to 10 carbon or aryl of 6 to 12 carbon atoms ;
- R 7 is alkyl of 1 to 10 carbon atoms (optionally substituted with halogen) ;
- aroyl is benzoyl and naphthoyl which is optionally substituted with one to three substituents each independently selected from the group halogen, cyano, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, -CF 3 , and phenyl; aryl is naphthyl, phenyl or phenyl optionally substituted with one to three substituents each independently selected from the group halogen, carboxy, alkyl of 1 to 10 carbon atoms, nitro, amino, alkoxy of 1 to 10 carbon atoms, and alkylamino of 1 to 10 carbon atoms;
- A is not a bond and W is not a carbon bearing a hydrogen
- R ⁇ and R 2 are H
- R 3 is selected from the group consisting of H, 4-methyl, 4-chloro, 4-nitro and 4- methoxy; and R 4 and R 5 are simultaneously methyl or ethyl
- R 4 is butyl
- R 3 is 4-halo (chloro, bromo, fluoro, or iodo) and R 4 is alkyl of 1 to 4 carbon atoms
- R x is selected from the group consisting of H, 2- methyl, 2-ethyl and 2-methoxy
- R 2 and R 5 are H
- R 3 is 4- dimethylamino and R 4 is 2-propyl; or pharmaceutically acceptable salts thereof.
- Preferred groups of compounds of Formula (I) of this invention are those in the subgroups: a) compounds having the general formula:
- R : , R 2 , R 3 , R 4 , and R 5 are as hereinbefore defined;
- R j , R 2 , R 3 , R 4 , and R 5 are as hereinbefore defined;
- R 1 , R 2 , R 3 , R 4 , and R 5 are as hereinbefore defined and W is a carbon bearing a hydrogen;
- R 1 , R 2 , R 3 , R 4 , and R 5 are as hereinbefore defined;
- R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as hereinbefore and W is a carbon bearing a hydrogen;
- R x , R 2 , R 3 , R 4 , R 5 and R 6 are as hereinbefore defined.
- More preferred compounds of Formula (I) of this invention are those in the subgroups:
- R 1 , R 2 , R 3 , R 4 , and R 5 are hereinbefore defined and W is a carbon bearing a hydrogen; and b) compounds having the general formula:
- R ⁇ , R 2 , R 4 and R 5 are hereinbefore defined, R 3 is alkoxy of 1 to 10 carbon atoms and W is a carbon bearing a hydrogen
- Specifically preferred compounds of this invention according to general Formula (I) are the following compounds or pharmaceutically acceptable salts thereof:
- this invention also provides a method of treating or inhibiting disorders associated with smooth muscle contraction, via potassium channel modulation in warm-blooded animals in need thereof, which comprises administering to said warm-blooded animals preferably mammals, most preferably humans, an effective amount of a compound of general Formula (II) or a pharmaceutically acceptable salt thereof.
- R : , R 2 , and R 3 are, independently, hydrogen, halogen, nitro, cyano, alkyl of 1 to 10 carbon atoms (optionally substituted with halogen) , cycloalkyl of 3 to 10 carbon atoms, -OR 7 , amino, alkylamino of 1 to 10 carbon atoms, -S0 3 H, -S0 2 NH 2 , -SONH 2 , -NHS0 2 R 7 , ft
- W is selected from the group consisting of carbon and nitrogen and wherein the carbon atom may be optionally substituted with -R ⁇ , -R 2 and -R 3 ;
- R 4 is alkyl of 1 to 10 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, aralkyl of 7 to 20 carbon atoms wherein the aryl group is optionally substituted with alkyl of 1 to 10 carbon atoms, nitro, halogen, cyano, -OR 7 ,
- R 5 is hydrogen, alkyl of 1 to 10 carbon atoms, for yl, alkanoyl of 2 to 7 carbon atoms, alkenoyl of 3 to 7 carbon atoms ,
- -C-OR 7 , -S0 2 R 7 , aroyl of 7 to 12 carbon atoms, arylalkenoyl of 9 to 20 carbon atoms, arylsulfonyl of 6 to 12 carbon atoms, arylalkanoyl of 8 to 12 carbon atoms or arylalkylsulfonyl of 7 to 12 carbon atoms;
- R 6 is alkyl of 1 to 10 carbon atoms, or aryl of 6 to 12 carbon atoms;
- R 7 is alkyl of 1 to 10 carbon atoms [optionally substituted with halogen) ;
- aroyl is benzoyl and naphthoyl which is optionally substituted with one to three substituents each independently selected from the group halogen, cyano, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, -CF 3 , and phenyl ;
- aryl is naphthyl, phenyl or phenyl optionally substituted with one to three substituents each independently selected from the group halogen, carboxy, alkyl of 1 to 10 carbon atoms, nitro, amino, alkoxy of 1 to 10 carbon atoms, and alkylamino of 1 to 10 carbon atoms; or pharmaceutically acceptable salts thereof.
- Preferred groups of compounds of Formula (II) of this invention for the method of treating disorders associated with smooth muscle contraction, via potassium channel modulation including pharmaceutically acceptable salts thereof are those in the subgroups :
- R : , R 2 , R 3 , R 4 , and R 5 are as hereinbefore defined for Formula (II) ;
- R 1 , R 2 , R 3 , R 4 , and R 5 are as hereinbefore defined for Formula (II) and W is a carbon bearing a hydrogen;
- R x , R 2 , R 3 , R 4 , and R 5 are as hereinbefore defined for Formula (II) ;
- R ⁇ , R 2 , R 3 , R 4 , and R 5 are as hereinbefore defined for Formula (II) ;
- R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as hereinbefore defined for Formula (II) and W is a carbon bearing a hydrogen;
- R x , R 2 , R 3 , R 4 , R 5 and R 6 are as hereinbefore defined for Formula (II) .
- Preferred compounds of Formula (II) of this invention for the method of treating disorders associated with smooth muscle contraction, via potassium channel modulation including pharmaceutically acceptable salts thereof are those in the subgroups: a) compounds having the general formula:
- R- L , R 2 , R 3 , R 4 , and R 5 are hereinbefore defined for Formula (II) and W is a carbon bearing a hydrogen; and b) compounds having the general formula:
- R- L , R 2 , R 4 and R 5 are hereinbefore defined for Formula (II) , R 3 is alkoxy of 1 to 10 carbon atoms and W is a carbon bearing a hydrogen.
- Halogen, or halo as used herein means chloro, fluoro, bromo and iodo.
- Alkyl as used herein means a branched or straight chain having from 1 to 10 carbon atoms and more preferably from 1 to 6 carbon atoms .
- Exemplary alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl and hexyl .
- Cycloalkyl as used herein means a saturated ring having from 3 to 10 carbon atoms and more preferably from 3 to 6 carbon atoms .
- Exemplary cycloalkyl rings include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
- Aryl as used herein means a homocyclic aromatic radical, whether or not fused, having 6 to 12 carbon atoms.
- Preferred aryl groups include phenyl, alpha-naphthyl and beta-naphthyl and the like optionally substituted with one to three substituents each independently selected from the group halogen, carboxy, alkyl of 1 to 10 carbon atoms, nitro, amino, alkoxy of 1 to 10 carbon atoms, and alkyl amino of 1 to 10 carbon atoms.
- Aroyl as used herein refers to -C(0)aryl where aryl is as previously defined. Examples include benzoyl and naphthoyl optionally substituted with one to three substituents each independently selected from the group halogen, cyano, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, -CF 3 and phenyl.
- Aralkyl as used herein means an aryl-alkyl group in which the aryl and alkyl group are previously defined.
- exemplary aralkyl groups include benzyl and phenethyl .
- Alkenyl as used herein means a branched or straight chain having from 2 to 12 carbon atoms and more preferably from 2 to 6 carbon atoms, the chain containing at least one carbon-carbon double bond.
- Alkenyl may be used synonymously with the term olefin and includes alkylidenes.
- Exemplary alkenyl groups include ethylene, propylene and isobutylene.
- Alkanoyl as used herein refers to -C(O) alkyl where alkyl is as previously defined.
- Alkenoyl as used herein refers to -C(O) alkenyl where alkenyl as previously defined.
- Alkoxy as used herein means an -O-alkyl group in which the alkyl group is as previously described.
- exemplary alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n- butoxy, and t-butoxy.
- Arylalkanoyl as used herein refers to a carbonyl group or radical directly bonded to an alkyl group of 1 to 10 carbon atoms which is terminally substituted by an aryl group as previously defined, for example phenylacetic acid.
- the aryl group is optionally substituted with one to three substituents each independently selected from the group halogen, cyano, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, CF 3 , and phenyl and substituted phenyl where the substituents are selected from halogen, cyano, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms and -CF 3 .
- Arylalkenoyl as used herein refers to a carbonyl group or radical directly bonded to an alkenyl group of 2 to 12 carbon atoms which is terminally substituted by an aryl group as previously defined.
- the aryl group is optionally substituted with one to three substituents each independently selected from the group halogen, cyano, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, - CF 3 , and phenyl and substituted phenyl where the substituents are selected from halogen, cyano, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms and -CF 3 .
- Arylsulfonyl as used herein refers to the radical -S0 2 aryl where aryl is as previously defined
- Arylalkylsulfonyl as used herein refers to the radical arylalkyl0 2 S- where arylalkyl is as previously defined.
- Phenyl as used herein refers to a 6-membered aromatic ring.
- aralkyl refers to an aryl group
- alkyl refers to the alkyl group as defined above .
- the range of carbon atoms defines the number of carbons in the carbon backbone and does not include carbon atoms occurring in substituent groups.
- specifically preferred compounds of this invention according to general Formula (II) are the specifically preferred compounds of Formula (I) or pharmaceutically acceptable salts thereof for the method of treating disorders associated with smooth muscle contraction via potassium channel modulation.
- Optical iso ers may be obtained in pure form by standard separation techniques or enantiomer specific synthesis. It is understood that this invention encompasses all crystalline forms of compounds of Formulae (I) and (II) .
- the pharmaceutically acceptable salts of the basic compounds of this invention are those derived from such organic and inorganic acids as: lactic, citric, acetic, tartaric, fumaric, succinic, maleic, malonic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic and similarly known acceptable acids .
- salts of the compounds in this invention may be formed with bases such as alkali metals (Na, K, Li) or alkaline earth metals (Ca or Mg) .
- the present invention accordingly provides a pharmaceutical composition which comprises a compound of Formula (II) of this invention in combination or association with a pharmaceutically acceptable carrier.
- the present invention provides a pharmaceutical composition which comprises an effective amount of a compound of this invention and a pharmaceutically acceptable carrier.
- the compounds of the present invention may be prepared according to one or more of the general processes outlined below.
- a polar solvent such as dimethylformamide (DMF) and the like
- Pd(O) reagent such as benzylchlorobis (triphenyl-phosphine) palladium (II) and the like in the presence of cuprous iodide to give a substituted-cyclobut-3-ene-
- R 5 and R 6 are hereinbefore defined.
- vinyl iodide 14 is reacted with stannane 1 in the presence of a Pd(O) reagent such as benzylchlorobis (triphenylphosphine) palladium (II) and the like in the presence of cuprous iodide to give styrenylcyclobutendione ethyl ester 15.
- a Pd(O) reagent such as benzylchlorobis (triphenylphosphine) palladium (II) and the like in the presence of cuprous iodide to give styrenylcyclobutendione ethyl ester 15.
- W, R ⁇ R 2 , and R 3 are hereinbefore defined.
- the compounds of Formula (I) and (II) and their pharmaceutically acceptable salts have been shown in this disclosure to relax smooth muscle. They are therefore useful in the treatment of disorders associated with smooth muscle contraction, disorders involving excessive smooth muscle contraction of the urinary tract (such as incontinence) or of the gastrointestinal tract (such as irritable bowel syndrome) , asthma, and hair loss.
- the compounds of Formula (I) and (II) are active as potassium channel activators which render them useful for treatment of peripheral vascular disease, congestive heart failure, stroke, anxiety, cerebral anoxia and other neurodegenerative disorders.
- compounds of Formula (I) and (II) mediate their biological effects by activating the large-conductance calcium-sensitive potassium channel (Bk ca ) or maxiK
- Compounds of the present invention are characterized by their potent smooth muscle relaxing properties in vi tro .
- the compounds of this invention exert their smooth muscle relaxatory activity via activation of potassium channels.
- the compounds of the present invention are unique in that they possess intrinsic selectivity for bladder tissue over vascular tissue as demonstrated by bladder/aorta IC 50 ratios (Table 1) .
- the present invention accordingly provides a pharmaceutical composition which comprises a compound of this invention in combination or association with a pharmaceutically acceptable carrier.
- the present invention provides a pharmaceutical composition which comprises an effective amount of a compound of this invention and a pharmaceutically acceptable carrier.
- the compositions are preferably adapted for oral administration. However, they may also be adapted for other modes of administration, for example, parenteral administration for patients suffering from heart failure.
- a composition of the invention is in the form of a unit dose.
- Suitable unit dose forms include tablets, capsules and powders in sachets or vials.
- Such unit dose forms may contain from 0.1 to 100 mg of a compound of the invention and preferably from 2 to 50 mg.
- Still further preferred unit dosage forms contain 5 to 25 mg of a compound of the present invention.
- the compounds of the present invention can be administered orally at a dose range of about 0.01 to 100 mg/kg or preferably at a dose range of 0.1 to 10 mg/kg.
- Such compositions may be administered from 1 to 6 times a day, more usually from 1 to 4 times a day.
- compositions of the invention may be formulated with conventional excipients, such as a filler, a disintegrating agent, a binder, a lubricant, a flavoring agent and the like. They are formulated in conventional manner, for example, in a manner similar to that used for known antihypertensive agents, diuretics and ⁇ -blocking agents .
- the present invention further provides a compound of the invention for use as an active therapeutic substance.
- Compounds of Formulae (I) and (II) are of particular use in the induction of smooth muscle relaxation.
- the present invention further provides a method of treating smooth muscle disorders in mammals, including man, which comprises administering to the afflicted mammal an effective amount of a compound or a pharmaceutical composition of the invention.
- Example 3 3- (Isopropyl-methyl-amino) -4- (4-metho ⁇ y-phenyl) -cvclobut-3- ene-1 , 2-dione
- 3- isopropoxy-4- (4-methoxy-phenyl) -cyclobut-3-ene-l, 2-dione (0.150 g, 0.609 mmol) and methyl-isopropylamine (0.07 L, 0.670 mmol) in acetonitrile (3 mL) were converted to the title compound (0.10 g, 63%) m.p.: 109-115°C;
- Example 5 3- (4-Methoxy-phenyl) -4- ⁇ 2 - (3-trifluoromethyl-phenyl) - ethylamino] -cvclobut-3-ene-l , 2-dione
- Step 2 3- isopropoxy-4- (4-methoxy-phenyl) -cyclobut-3-ene-l, 2-dione
- Example 7 3- (4-Methoxy-phenyl) -4- (2-phen l-propylamino) -cvclobut-3- ene-1, 2-dione
- 3- isopropoxy-4- (4-methoxy-phenyl) -cyclobut-3-ene-l, 2-dione (0.150 g, 0.609 mmol) and 2-methyl-2-phenyl-ethylamine (0.165 g, 1.22 mmol) in ethanol (2 mL) were converted to the title compound (0.130 g, 66%) m.p.: 215.4-216.2°C;
- Examples 13-20 are prepared in a two-step procedure using the conditions described in Examples 1 or 9 using the appropriate aryl iodide, 3 -isopropoxy-4- (tri-n- butylstannyl) -3-cyclobutene-l , 2-dione, and the appropriate amine .
- Example 13 3- (1, 1-Dimethyl-propylamino) -4- (3, 4-dimethoxy-phenyl) - cyclobut-3 -ene-1, 2-dione.
- Example 19 1-Dimethyl-propylamino) -4- (2-bromo-4, 6-dimethoxy- phenyl) -cyclobut-3-ene-1 , 2-dione.
- the enolate solution was cooled to -78°C and added by cannula to a cooled (-78°C) flask containing diethyl squarate (1.50 mL, 10.13 mmol) in THF/diethyl ether (1:1 ratio, 20 mL) .
- the reaction was stirred for 15 min. at -78°C and was then allowed to warm to room temperature over a 1 hour period.
- the reaction was concentrated to give a residue which was partitioned between 0.1 N HCl and ethyl acetate.
- the organic phase was washed with brine, dried (MgS0 4 ) and concentrated to give crude product.
- Example 22 3- (4-Bro o-phenyl) -4- (1, 2 , 2-trimethyl-propylamino) - cvclobut-3 -ene-1 , 2-dione
- 2-dione 290 mg, 0.983 mmol
- 2-amino-3 , 3-dimethylbutane 263 ⁇ L, 1.96 mmol
- reaction mixture was diluted with isopropyl alcohol, filtered, washed with an excess of isopropyl alcohol, then dried under high vacuum at 65°C, affording a light yellow solid (225 mg, 68%) : m.p.
- reaction mixture was heated to 100°C, stirred 18 hours, then worked up by dilution with toluene (150 mL) , followed by consecutive extraction with ammonium hydroxide (3 x 50 mL) and brine (50 mL) .
- the organic phase was further diluted with ethyl acetate (300 mL) , dried over MgS0 4 , filtered through a short pad of diatomaceous earth, and then concentrated onto silica gel .
- submission to flash chromatography multiple gradient elution with ether-petroleum ether afforded a yellow solid which was triturated with ether-hexanes .
- the smooth muscle (bladder) relaxing activity of the compounds of this invention was established in accordance with standard pharmaceutically accepted test procedures with representative compounds as follows:
- Sprague-Dawley rats (150-200 g) are rendered unconscious by C0 2 asphyxiation and then euthanized by cervical dislocation. The bladder is removed into warm
- the preparations which usually exhibit small spontaneous contractions, are allowed to recover for a period of 1 hour prior to a challenge with 0.1 ⁇ M carbachol .
- the carbachol is then washed out and the tissue allowed to relax to its resting level of activity.
- an additional 15 mM KC1 are introduced into the tissue bath.
- This increase in KC1 concentration results in a large increase in the amplitude of spontaneous contractions (and initiation of contractions in previously quiescent strips) superimposed upon a small increase in basal tone.
- incremental increases in the concentration of test compound or vehicle are introduced into the tissue bath. Contractile activity is measured for each compound or vehicle concentration during the last minute of a 30 minute challenge.
- the isometric force developed by the bladder strips is measured using a concentration required to elicit 50% inhibition of pre-drug contractile activity (IC 50 concentration) and is calculated from this concentra-tion- response curve.
- IC 50 concentration concentration required to elicit 50% inhibition of pre-drug contractile activity
- the maximum percentage inhibition of contractile activity evoked by a test compound is also recorded for concentrations of test compound less than or equal to 30 ⁇ M.
- the smooth muscle (aorta) relaxing activity of the compounds of this invention was established in accordance with standard pharmaceutically accepted test procedures with representative compounds as follows:
- the aorta is cleaned of fat and loose adventitia and cut into rings 3-4 mm in width.
- the rings are subsequently suspended between two stainless steel wire tissue holders in a 10 ml tissue bath.
- One wire tissue holder is attached to a fixed hook while the other is attached to an isometric force transducer. Resting tension is set at 1 g .
- the tissues are to recover for a period of 60 mins . prior to beginning the experiment. Tissues are challenged with PSS containing 25 mM KCl to elicit a contracture. The tissues are then washed repeatedly with fresh PSS over a period of 30 mins. and allowed to recover to baseline tension.
- PSS containing 30-35 mM KCl is then introduced into the tissue bath to evoke a contracture that is allowed to stabilize for not less than 45 minutes.
- Other stimuli such as norepine-phrine, PGF2a, histamine, angiotensin II, endothelin or PSS containing 80 mM KCl may also be used to evoke a contracture as necessary.
- Increasing concentrations of test compound or vehicle are then added to the tissue bath in a cumulative fashion.
- Isometric force development by the aortic rings is measured using a force transducer and recorded on a polygraph.
- the percentage inhibition of contractile force evoked by each concentration of a given test compound is used to generate a concentration-response curve.
- the compounds of this invention are selective for bladder tissue and have a pronounced effect on smooth muscle contractility and are useful in the treatment of urinary incontinence, irritable bladder and bowel disease, asthma, stroke, and similar diseases as mentioned above, which are amenable to treatment with potassium channel activating compounds by administra-tion, orally, parenterally, or by aspiration to a patient in need thereof .
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU21635/00A AU2163500A (en) | 1998-12-04 | 1999-12-03 | 4-3-substituted-amino-cyclobut-3-ene-1,2-diones and use for influencing smooth muscle contraction |
JP2000586679A JP2003529532A (en) | 1998-12-04 | 1999-12-03 | 4-3-Substituted-amino-cyclobut-3-ene-1,2-dione and uses for affecting smooth muscle contraction |
EP99965976A EP1135365A1 (en) | 1998-12-04 | 1999-12-03 | 4-3-substituted-amino-cyclobut-3-ene-1,2-diones and use for influencing smooth muscle contraction |
CA002350888A CA2350888A1 (en) | 1998-12-04 | 1999-12-03 | 4-3-substituted-amino-cyclobut-3-ene-1,2-diones and use for influencing smooth muscle contraction |
BR9915899-0A BR9915899A (en) | 1998-12-04 | 1999-12-03 | Compound, pharmaceutical composition and method for treating or inhibiting disorders associated with smooth muscle contraction. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20601298A | 1998-12-04 | 1998-12-04 | |
US09/206,012 | 1998-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000034230A1 true WO2000034230A1 (en) | 2000-06-15 |
Family
ID=22764622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/028618 WO2000034230A1 (en) | 1998-12-04 | 1999-12-03 | 4-3-substituted-amino-cyclobut-3-ene-1,2-diones and use for influencing smooth muscle contraction |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1135365A1 (en) |
JP (1) | JP2003529532A (en) |
AU (1) | AU2163500A (en) |
BR (1) | BR9915899A (en) |
CA (1) | CA2350888A1 (en) |
WO (1) | WO2000034230A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005009955A1 (en) * | 2003-07-31 | 2005-02-03 | Hetero Drugs Limited | Ezetimibe polymorphs |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
US11926616B2 (en) | 2018-03-08 | 2024-03-12 | Incyte Corporation | Aminopyrazine diol compounds as PI3K-γ inhibitors |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010018795A (en) * | 2008-06-10 | 2010-01-28 | Sumitomo Chemical Co Ltd | Polymer with oxo carbon group |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995014005A1 (en) * | 1993-11-17 | 1995-05-26 | American Home Products Corporation | Diaminocyclobutene-3,4-diones as smooth muscle relaxants |
WO1995034556A1 (en) * | 1994-06-10 | 1995-12-21 | American Home Products Corporation | Cyclobut-3-ene-1,2-dione derivatives as smooth muscle relaxants |
WO1996000725A1 (en) * | 1994-06-28 | 1996-01-11 | American Home Products Corporation | (3,4-dioxocyclobuten-1-yl)chromene, indene, and dihydronaphthalenone derivatives as smooth muscle relaxants |
EP0761643A2 (en) * | 1995-09-05 | 1997-03-12 | Fuji Xerox Co., Ltd. | Cyclobutenedione derivative, manufacturing method thereof and non-linear optical device containing the same |
-
1999
- 1999-12-03 BR BR9915899-0A patent/BR9915899A/en not_active Application Discontinuation
- 1999-12-03 EP EP99965976A patent/EP1135365A1/en not_active Withdrawn
- 1999-12-03 WO PCT/US1999/028618 patent/WO2000034230A1/en not_active Application Discontinuation
- 1999-12-03 CA CA002350888A patent/CA2350888A1/en not_active Abandoned
- 1999-12-03 AU AU21635/00A patent/AU2163500A/en not_active Abandoned
- 1999-12-03 JP JP2000586679A patent/JP2003529532A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995014005A1 (en) * | 1993-11-17 | 1995-05-26 | American Home Products Corporation | Diaminocyclobutene-3,4-diones as smooth muscle relaxants |
WO1995034556A1 (en) * | 1994-06-10 | 1995-12-21 | American Home Products Corporation | Cyclobut-3-ene-1,2-dione derivatives as smooth muscle relaxants |
WO1996000725A1 (en) * | 1994-06-28 | 1996-01-11 | American Home Products Corporation | (3,4-dioxocyclobuten-1-yl)chromene, indene, and dihydronaphthalenone derivatives as smooth muscle relaxants |
EP0761643A2 (en) * | 1995-09-05 | 1997-03-12 | Fuji Xerox Co., Ltd. | Cyclobutenedione derivative, manufacturing method thereof and non-linear optical device containing the same |
Non-Patent Citations (4)
Title |
---|
KOEHLER, KLAUS ET AL: "Iminocarbon dianions of the C4-series with cyanoimino groups", CHEM. BER. (1985), 118(5), 1903-16, XP002133744 * |
RIED, WALTER ET AL: "Reactions of cyclobutenediones. XXXVIII. Reactions of cyclobutenediones with aziridine", JUSTUS LIEBIGS ANN. CHEM. (1975), (10), 1863-72, XP002133743 * |
RIED, WALTER ET AL: "Reactions with cyclobutenediones. IV. Reaction of 2-bromo-1-phenyl-1-cyclobutene-3,4-dione and o-phenylenediamines", CHEM. BER. (1969), 102(4), 1422-30, XP002133741 * |
RIED, WALTER ET AL: "Reactions with cyclobutenediones. V. Reaction of 2-bromo-1-cyclobutene-3,4-dione with primary, secondary, and tertiary aromatic monoamines and p-diamines", CHEM. BER. (1969), 102(4), 1431-8, XP002133742 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005009955A1 (en) * | 2003-07-31 | 2005-02-03 | Hetero Drugs Limited | Ezetimibe polymorphs |
US11926616B2 (en) | 2018-03-08 | 2024-03-12 | Incyte Corporation | Aminopyrazine diol compounds as PI3K-γ inhibitors |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
Also Published As
Publication number | Publication date |
---|---|
EP1135365A1 (en) | 2001-09-26 |
BR9915899A (en) | 2001-08-21 |
AU2163500A (en) | 2000-06-26 |
JP2003529532A (en) | 2003-10-07 |
CA2350888A1 (en) | 2000-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0729457B1 (en) | Diaminocyclobutene-3,4-diones as smooth muscle relaxants | |
US5532245A (en) | Substituted N-heteroaryl-1,2-diaminocyclobutene-3,4-dione compounds | |
US6465523B1 (en) | 4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers | |
DE10021246A1 (en) | New N-substituted benzamide derivatives are tyrosine kinase KDR and FLT inhibitors useful e.g. for treating tumors, psoriasis, rheumatoid arthritis, diabetic retinopathy or liver sclerosis | |
JP3397320B2 (en) | Condensed imidazolium derivatives | |
WO2005004803A2 (en) | Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease | |
JP2007515404A (en) | Benzyl ether and benzylamino β-secretase inhibitors for the treatment of Alzheimer's disease | |
EP0124476B1 (en) | Carboxamides, process for their preparation and pharmaceutical preparations containing them | |
JPS62167752A (en) | Phenylacetonitrile derivative, medicinal composition and calcium ion antagonistic or antihypertensive action acceleration in mammal animals | |
JPH10182583A (en) | New hydroxamic acid derivative | |
JP2000063363A (en) | New triazole derivative | |
EP0888357A1 (en) | Azaspiro derivatives | |
JP2005507381A (en) | Major ring-substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders | |
WO2000034230A1 (en) | 4-3-substituted-amino-cyclobut-3-ene-1,2-diones and use for influencing smooth muscle contraction | |
JPH024739A (en) | Novel benzocycloheptene derivative, drug containing the same and production thereof | |
JPS58116434A (en) | Substituted phenoxyalkanol amines and phenoxyalkanol-cycloalkylamines | |
JPS6222768A (en) | Substituted tetrahydroisoquinoline derivative | |
KR102606737B1 (en) | Novel benzimidazolone compounds and their medicinal uses | |
MXPA01005424A (en) | 4-3-substituted-amino-cyclobut-3-ene-1,2-diones and use for influencing smooth muscle contraction | |
JPH05202054A (en) | Aminomethyl-substituted 2,3-dihydropyrano(2,3-b)pyridine | |
CN107428682A (en) | Amide derivatives, its preparation method and its purposes in medicine | |
US6458823B1 (en) | Diaminopyrazoles | |
US6319941B1 (en) | Diaminopyrazoles | |
JP2003128548A (en) | Medicinal composition containing condensed imidazolium derivative | |
AU727217B2 (en) | Heterocyclylmethylamino derivatives of cyclobutene-3,4- diones as potassium channel modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999965976 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2350888 Country of ref document: CA Ref document number: 2350888 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 21635/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 511809 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/005424 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2000 586679 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 99815993.X Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1999965976 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999965976 Country of ref document: EP |